[1]
D. Clercq, Molecular Targets for Antiviral Agents. Vol. 297 (2000) p.1.
Google Scholar
[2]
E. de Clercq, P. Herdewijn, Nat. Rev. Drug Discov. Vol. 1 (2002), p.13.
Google Scholar
[3]
B. Öberg, Antiviral Res. Vol. 71 (2006) p.90.
Google Scholar
[4]
Y.S. Skoblov, I.L. Karpenko, E.A. Shirokova, K.E. Popov, V.A. Andronova, G.V. Galegov, M.K. Kukhanova, Antiviral Res. Vol. 63 (2004), p.107.
DOI: 10.1016/j.antiviral.2004.03.001
Google Scholar
[5]
A. Albert, Nature, Vol. 182 (1958), p.421.
Google Scholar
[6]
H. Bundgaard, Drugs of the Future Vol. 16 (1991), p.443.
Google Scholar
[7]
J. Balzarini, S. Aquaro, T. Knispel, C. Rampazzo, V. Bianchi, C. -F. Perno, E. De Clercq, C. Meier, Mol. Pharmacol. Vol. 58 (2000) p.928.
DOI: 10.1124/mol.58.5.928
Google Scholar
[8]
S. Yang, C. Pannecouque, P. Herdewijn, Chemistry Biodiversity. Vol. 9 (2012), p.2186.
Google Scholar
[9]
S.R. Shaver, J.L. Rideout,W. Pendergast, J.G. Douglass, E.G. Brown, J.L. Boyer, R.I. Patel, C.C. Redick, A.C. Jones, M. Picher, B.R. Yerxa, Purinergic Signalling Vol. 1 (2005), p.183.
DOI: 10.1007/s11302-005-0648-2
Google Scholar
[10]
W. Pendergast, B.R. Yerxa, J.G. Douglass, S.R. Shaver, R.W. Dougherty, C.C. Redick, I.F. Sims, J.L. Rideout, Bioorg. Med. Chem. Lett. Vol. 11 (2001), p.157.
DOI: 10.1016/s0960-894x(00)00612-0
Google Scholar
[11]
S. Mohamady, S.D. Taylor, J. Org. Chem. Vol. 76 (2011), p.6344.
Google Scholar
[12]
S. Mohamady, A. Desoky, S.D. Taylor, Org. Lett. Vol. 14 (2012), p.402.
Google Scholar
[13]
A. Ohkubo, N. Tago, A. Yokouchi, Y. Nishino, K. Yamada, H. Tsunoda, K. Seio, M. Sekine, Org. Lett. Vol. 14 (2012), p.10.
DOI: 10.1021/ol2026075
Google Scholar